secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001140361-23-053088
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q3 net loss widens to $4.0M, revenue down 30%; FemaSeed gets FDA clearance
--------------------------------------------------------------------------------

- Net loss of $4.0M ($0.26/share) vs $3.0M ($0.25) in Q3 2022.
- Revenue $244K, down 30% from $347K; U.S. units down 18.4% YoY.
- Raised $11.3M via warrant exercises and ATM; cash $8.7M sufficient for >12 months.
- FDA 510(k) clearance for FemaSeed infertility treatment; FINALE trial for FemBloc enrolling.
- Gross margin improved to 64.7% from 62.2% on manufacturing efficiencies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123053088/0001140361-23-053088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123053088/ef2001466_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-053088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer